MELBOURNE, Australia, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, an Australian private company commercializing evidence-based nutraceuticals and pharmaceuticals based on tocotrienols, today announced the appointment of Natural Alternatives International, Inc. (NAI) in San Marcos, California to manufacture its nutraceutical products for the US market.
NAI is a highly regarded contract manufacturer which is certified to be compliant with USFDA current good manufacturing practices (cGMP), with considerable experience in developing customized nutritional supplements.
"Gordagen is delighted to enter into an agreement with a manufacturer with significant capability, capacity and global reach. NAI's extensive knowledge of nutraceuticals and strong partnering philosophy will be a great support for Gordagen as we rapidly progress our US market entry," said Dr Glenn Tong, Managing Director and CEO, Gordagen.
NAI develop customized formulations, handle quality assurance testing and manufacturing and packaging capabilities. After an extensive search, it was NAI's experience with existing global supplements and the groups' ability to handle large batch requirements for significant markets that was of particular interest to Gordagen.
Gordagen is currently developing tocotrienol-based nutraceuticals backed by clinically regulated research, for the muscle soreness, exercise endurance and heart health markets. It has a diverse prescription pharmaceutical portfolio, covering core indications of cardiovascular disease, diabetes and hypertension. The Company's proprietary MELT3™ melt-then-swallow technology is combined with a unique formulation of tocotrienols to enable improved bioavailability.
"Gordagen intends to launch its first product into the US next year, closely followed by other countries. Knowing that we have a well-recognized and supportive manufacturing partner in the US helps to mitigate portfolio risk," Dr Tong said.
NAI's manufacturing facilities are based in San Marcos, California. The group also has operations in Switzerland and Japan, enabling the opportunity for manufacturing support in other major global markets.
The group will manufacture Gordagen's MELT3™ tablets initially, supplying the ongoing clinical development program as well as commercial launch. Gordagen's additional nutraceutical products requirements will follow.
"We were very impressed with the evidence-based nutraceuticals which forms the Gordagen product pipeline and look forward to working closely in partnership with them to make their entry into the US market a success," commented Mr. Mark LeDoux, JD, the Chief Executive Officer and Chairman of the Board of NAI.
About Gordagen Pharmaceuticals Pty Ltd
Gordagen Pharmaceuticals is a privately-held Australian company developing and commercializing novel supplements and prescription medicines based on natural tocotrienols, found in vitamin E. The Company has developed a novel approach to delivering highly potent tocotrienols to target tissues using its proprietary and patent-pending "melt-then-swallow" delivery technology (MELT3TM). The Company is focusing on tocotrienols with wide therapeutic potential, initially targeting heart health, muscle soreness and exercise endurance.
CONTACT: Investor and Media Enquiries: Company Dr Glenn Tong Managing Director & CEO Tel: +61 (0) 412 193 350 Australia Paris Brooke Bt Novo Pty Ltd Tel: +61 (0) 407 715 574 United States David Burke The Ruth Group O: 646.536.7009 C: 917-618-2651